it currently owns about three-quarters of the interferon market in
hepatitis C, Bloomberg says. Plus, Merck’s trials
for Victrelis tested the drug in combination with Peg-Intron, so having Roche put its stamp on Victrelis as a Pegasys add-on could help offset the lack of data there. That’s what Sanford Bernstein’s Tim Anderson figures: “Now, with Roche on board, this potential shortcoming gets more than removed, in our opinion.